Pathology This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 40.

Salvage Radiotherapy and Cisplatin for Triple Negative Breast Cancer: A Multi-Centre Study
Conclusions: Patients with locally advanced, triple-negative breast cancer who progressed during or shortly after NAC had a high clinical response rate when treated with salvage XRT+ CDDP. In patients who underwent surgery after salvage treatment, 50% achieved pCR. Salvage treatments appeared to be relatively well tolerated and safe.This subset of patients is at very high risk for tumour recurrence. Prospective, multi-centre studies of concurrent cisplatin and radiotherapy in the setting of locally advanced, triple negative breast cancer are needed to further assess efficacy and toxicity.Citation Information: Cancer Res 20...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Lee, J., Brackstone, M., Gandhi, S., Arce, S. C., Dinniwell, R. Tags: Poster Session 4 - Treatment: Radiotherapy Source Type: research

Identifying women at increased risk for breast cancer using the electronic health record in an integrated health system
Women at increased risk for breast cancer (BC) are eligible to take selective estrogen receptor modulators (SERMs) to reduce their risk; Food and Drug Administration (FDA) approval of tamoxifen or raloxifene for BC risk reduction and American Society of Clinical Oncology (ASCO) guidelines for the use of SERMs recommend the two drugs for any woman over the age of 35 years with a 5-year risk of 1.67% or greater, but identifying those women can be both challenging and costly. We used an electronic database (Centricity RIS-IC) from the Geisinger Health System (GHS) Department of Radiology with 77,000 women ages 35–90 yea...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Leader, J., Bengier, A., Darer, J., Stark, A., Vogel, V. Tags: Poster Session 4 - Epidemiology, Risk, and Prevention: Epidemiology, Risk, and Prevention - Other Source Type: research

Estrogen and Avoidance of Invasive Breast Cancer, Coronary Heart Disease and All-cause Mortality. Public Health Impact of Estrogen Guidelines for Women entering Menopause.
CONCLUSION.1. Estrogen therapy could reduce thousands of BrCa, CHD and AC-Mortality events annually, just in North America. These gains are in addition to the established quality of life improvement for millions of women due to [E].2. Of particular importance is the [E] effect on reduction of iBrCa rates, particularly significant for women without PHBBD, confirming the new paradigm of Dual E effect for human BrCa [Ref 3].3. These substantial Public Health gains associated with [E] may justify changing policy to incorporate [E] into HRT guidelines for appropriately selected women.4. Accelerated research to optimize [E] form...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Ragaz, J., Wilson, K., Shakeraneh, S., Budlovsky, J., Wong, H. Tags: Poster Session 4 - Epidemiology, Risk, and Prevention: Epidemiology, Risk, and Prevention - Other Source Type: research

Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer
This study aims were to identify genetic anomalies in BRCA1 and BRCA2 by completely re-sequencing 200 kilobases surrounding BRCA1 and BRCA2 using targeted massively parallel sequencing, or next-generation sequencing.For this study, DNA was used from 10 individuals referred for genetic testing after meeting the criteria for inherited breast cancer, and had been screened for BRCA1 and BRCA2 mutations by the Hunter Area Pathology Service (Newcastle, NSW, Australia). All individuals used for this study did not harbour causative genetic changes in the coding regions of BRCA1 or BRCA2. Targeted next-generation paired-end sequenc...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Wong-Brown, M., Li, S., Wilkins, M., Avery-Kiejda, K., Bowden, N., Scott, R. Tags: Poster Session 4 - Epidemiology, Risk, and Prevention: Familial Breast Cancer - Molecular Genetics Source Type: research

miR-187 is an independent prognostic factor in lymph node-positive breast cancer patients.
Conclusions: miR-187 expression in breast cancer leads to the formation of a more aggressive, invasive phenotype and acts as an independent predictor of outcome.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-09-06.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: O'Connor, D., Mulrane, L., Brennan, D., Madden, S., Gremel, G., McGee, S., McNally, S., Martin, F., Crown, J., Jirstrom, K., Higgins, D., Gallagher, W. Tags: Poster Session 4 - Prognostic and Predictive Factors: Prognostic Factors - Preclinical Source Type: research

A comparison of MRI, PET-CT, and ultrasonography for evaluation of tumor response to neoadjuvant chemo-therapy in patients with locally advanced breast cancer
CONCLUSIONS: Out of the three radiologic tools, examined in the present study, no single test was clearly superior in evaluating the tumor response of either the primary tumor or nodal metastases. Future investigations are warranted to identify the tumor and treatment factors which may influence the specificity, sensitivity and predictive values of each test.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-03-09.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Boothe, D., Stessin, A., Nagar, H., Hayes, M. Tags: Poster Session 4 - Detection/Diagnosis: Breast Imaging - Other Methods Source Type: research

Molecular Breast Imaging: the sensitivity of breast-specific gamma imaging (BSGI) as a diagnostic adjunct to mammography and ultrasound in a triple assessment protocol
Conclusions: Of the three imaging modalities, BSGI provided the highest independent sensitivity and when added to the diagnostic workup, BSGI detected an additional 14 malignancies, increasing the sensitivity from 90% to 98%. Although it is beyond the scope of this work, it is interesting to note that the cost of the BSGI procedure is relatively low, about $320, and that in this population the BSGI specificity was 74%. In summary, when added to the diagnostic work up of patients in the community breast cancer, BSGI can improve the detection of breast malignancy when compared to mammography and ultrasound alone.Citation Inf...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Weigert, J., Kieper, D., Stern, L., Bohm-Velez, M. Tags: Poster Session 4 - Detection/Diagnosis: Molecular, Functional, and Novel Imaging Source Type: research

Early Optical Tomography Changes Predict Breast Cancer Response to Neoadjuvant Chemotherapy
Conclusions: DOT change is an early predictor of response to NACT as measured by the RCB score. We found a significant linear association between the RCB index and the 2-week change in [Hb] and SC. Significantly different changes in DOT parameters were associated with the other RCB classifications. Additional recruitment is ongoing and differences by tumor subtype will be evaluated.*These two authors contributed equally to this studyCitation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-02-07.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Lim, E., Gunther, J., Flexman, M., Kim, H., Hibshoosh, H., Kalinsky, K., Crew, K., Maurer, M., Taback, B., Feldman, S., Brown, M., Refice, S., Alvarez-Cid, M., Hielscher, A., Hershman, D. Tags: Poster Session 4 - Detection/Diagnosis: Molecular, Functional, and Novel Imaging Source Type: research

Ductolobular breast carcinoma and the role of preoperative magnetic resonance imaging
Conclusion: For patients diagnosed with invasive ductolobular breast cancer, the probability of detecting clinically relevant additional findings on MRI is high. Preoperative MRI should therefore be part of the routine work up of this breast cancer type.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-01-17.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Postma, E., El, S. M., Verkooijen, H., Witkamp, A., van den Bosch, M., van Hillegersberg, R., van Diest, P. Tags: Poster Session 4 - Detection/Diagnosis: Breast Imaging - MRI Source Type: research

Can MRI predict the response to neoadjuvant chemotherapy in breast cancer accurately?
Conclusions: Early responders and tumours achieving complete response on MRI are significant predictors of histopathological response. Serial MRI is predictive of response to NAC and possibly also a predictor of DFS. In this series MRI overestimated residual disease in nearly 1 in 5 patients.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-01-14.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Fatayer, H., Kim, B., Dall, B., Sharma, N., Manuel, D., Shabaan, A., Perren, T., Velikova, G., Horgan, K., Lansdown, M. Tags: Poster Session 4 - Detection/Diagnosis: Breast Imaging - MRI Source Type: research

High-resolution diffusion weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3 Tesla
Diffusion weighted imaging (DWI) has shown potential for separating malignant from benign lesions on breast MRI, theoretically improving the specificity of the breast MRI exam. However, standard DWI is hampered by multiple factors in the breast which limit utility in clinical practice. A readout segmented diffusion technique (RESOLVE)(1) permits the use of extremely short echo spacing and resamples uncorrectable data using a real-time navigator, reducing image distortion and potentially providing more accurate apparent diffusion coefficient (ADC) within lesions. In order to study the potentially utility of this method agai...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Wisner, D., Rogers, N., Deshpande, V., Newitt, D., Laub, G., Porter, D., Joe, B., Hylton, N. Tags: Poster Session 4 - Detection/Diagnosis: Breast Imaging - MRI Source Type: research

Evaluation of 3D T2-weighted Breast MRI
Conclusion: CUBE provides equivalent contrast and improved resolution in the breast in comparison to FSE. While T2-weighted images will continue to be an adjunct to DCE images, 3D T2-weighted sequences like CUBE have the potential to expand the contribution of T2-weighted images to the characterization of benign and malignant lesions in the breast.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-01-06.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Moran, C., Hargreaves, B., Saranathan, M., Daniel, B. Tags: Poster Session 4 - Detection/Diagnosis: Breast Imaging - MRI Source Type: research

Triple Negative Breast Cancer and BRCA Status: Implications for Genetic Counseling
CONCLUSION: TNBC was strongly associated with BRCA1 status, but not with BRCA2 status. Statistically significant numbers of patients with BRCA mutations have a TNBC profile. These patients should therefore be referred to clinical genetics for further evaluation and possible testing.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-08-06.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Haque, R., Alvarado, M., Ahmed, S., Shi, J., Chung, J., Avila, C., Zheng, C., Tiller, G. Tags: Poster Session 3 - Epidemiology, Risk, and Prevention: Epidemiology - Genetic and Molecular Source Type: research

PTEN mRNA positivity using in situ measurements is associated with better outcome in Tamoxifen treated breast cancer patients.
Conclusion: Initial data suggests that PTEN mRNA expression may be predictive of favorable response to endocrine therapy in breast carcinomas. However, validation in larger independent cohorts is required.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-06-25.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Schalper, K., Li, K., Rimm, D. Tags: Poster Session 3 - Prognostic and Predictive Factors: Response Predictions - Biomarkers and Other Factors Source Type: research

Poor prognosis early breast cancer: pathological characteristics of the Unicancer-PACS08 trial including patients treated with docetaxel or ixabepilone in adjuvant setting
Conclusion: The Unicancer-PACS08 patient cohort is mainly composed of TNBC that harbour distinct pathological features. Description of the PACS08 collection provides a solid basis for translational research projects, which have been initiated with regards to genomic instability and DNA damage repair, immune system, and biomarker studies to identify new therapeutic targets.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-05-07.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Lacroix-Triki, M., Delree, P., Filleron, T., Penault-Llorca, F., Bor, C., Mery, E., Maisongrosse, V., Genin, P., Jacquemier, J., Reyre, J., Caveriviere, P., Quintyn-Ranty, M.-L., Escourrou, G., Mesleard, C., Lemonnier, J., Martin, A.-L., Campone, M. Tags: Poster Session 3 - Tumor Cell and Molecular Biology: Tumor Heterogeneity/Molecular Subclassification Source Type: research

Automated analysis of Her2 FISH using combined Immunofluorescence and FISH signals
Conclusion: The observed variability in algorithm performance between the different cases was due to the fact that error root causes were case dependent. For instance, the main cause of over-counting errors was image noise and artifacts. On the other hand, the main cause of under-counting was low image contrast, especially in highly amplified cases. These results are an early indication of the promise of automatic dot counting applied to breast cancer slides multiplexed for Her2 IF and FISH.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-05-06.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Seppo, A., Al-Kofahi, Y., Padfield, D., Ha, T., Jun, N., Kyshtoobayeva, A., Kaanumalle, L., Corwin, A., Henderson, D., Kamath, V., McCulloch, C., Hollman, D., Bloom, K. Tags: Poster Session 3 - Tumor Cell and Molecular Biology: Tumor Heterogeneity/Molecular Subclassification Source Type: research

HER2 Expression and Gene copy analysis by Immunofluorescence and Fluorescence in situ Hybridization, on a Single formalin-fixed paraffin-embedded tissue section
Conclusion: The reported incidence of intratumoral HER2 amplification heterogeneity is as high as 30%. The challenges associated with tumor heterogeneity may benefit from a standardize analysis method. Using integrated images generated by this system, pathologist is able to select the appropriate cells for HER2 copy number enumeration based on the expression level of HER2 protein, in the same cell, allowing rapid identification of intratumoral heterogeneity.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-05-05.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Ha, T., Seppo, A., Ginty, F., Kenny, K., Henderson, D., Kyshtoobayeva, A., Gerdes, M., Larriera, A., Liu, X., Corwin, A., Zingelewicz, S., Lazare, M., Jun, N., Kyshtoobayeva, A., Chow, C., Al-Kofahi, Y., Hollman, D., Bloom, K. Tags: Poster Session 3 - Tumor Cell and Molecular Biology: Tumor Heterogeneity/Molecular Subclassification Source Type: research

Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) versus clinical subtypes for breast cancer among 621 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial
Conclusions: Marked differences are observed between BluePrint and MammaPrint (microarray based) breast cancer subtypes and centrally re-assessed pathological surrogates (based on ER, PR, HER2 & Ki67). The greatest discordance is seen in the sub-stratification of Luminal patients, and in the HR+/HER2+ patients. The observed subtype discrepancies may have an important impact on treatment decision making.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-05-02.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Viale, G., Slaets, L., de Snoo, F., van't, V. L., Rutgers, E., Piccart, M., Bogaerts, J., van den Akker, J., Stork-Sloots, L., Engelen, K., Russo, L., Dell'Orto, P., Cardoso, F. Tags: Poster Session 3 - Tumor Cell and Molecular Biology: Tumor Heterogeneity/Molecular Subclassification Source Type: research

A tri-modality imaging assessment algorithm to evaluate neoadjuvant therapy response in patients with operable breast cancer
Conclusions: A tri-modality imaging scoring algorithm is predictive of complete pathologic response. This algorithm will be tested in a developing prospective trial that will also assess the additive value of tumor bed biopsy in patients who achieve a score of 5 or less.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-03-03.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Umphrey, H., Bernreuter, W., Bland, K., Carpenter, J., Falkson, C., Forero, A., Keene, K., Krontiras, H., Meredith, R., Urist, M., De Los Santos, J. Tags: Poster Session 3 - Detection/Diagnosis: Radiology - Tumor Monitoring Source Type: research

Ultrasound as single mode of imaging may miss significant pathology in symptomatic women aged 35-39
In conclusion for the vast majority of patients in this group mammography does not add to the evaluation on presentation at symptomatic breast clinic. However this study identified a case (1 patient in 96) where significant disease could have been missed had a mammogram not been undertaken. The acceptable level of such false negative assessments with ultrasound only imaging in women under 40 must be further evaluated.1Best practice diagnostic guidelines for patients presenting with breast symptoms Alexis M Willett, Michael J Michell, Martin J R Lee, November 2010Printed by Breakthrough Breast Cancer, www.dh.gov.uk/publicat...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Baker, E., Masudi, T., Waterworth, A. Tags: Poster Session 3 - Detection/Diagnosis: Breast Imaging - Mammography Source Type: research

A web-based data management system for a multicenter international breast cancer oriented blood, tissue, and data biobank
Conclusion: This Biobank Management System was designed by a multidisciplinary team to improve and streamline the workflow for each member of the biobank by: allowing preregistration capabilities before consenting individuals or collecting samples, automatic generation of clinical and sample ID labels, and real-time statistics with certified secure sensible information confidentiality. This system's value is its wide range of uses, from the day-to-day management of a multicenter biobank to the storage of detailed clinical cancer-related data in a user-friendly and intuitive data entry environment.Citation Information: Canc...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Margossian, A., Saadjian, H., Mira, A., Contreras, A., Rimawi, M., Margossian, M., Scheurer, M., Osborne, K., Gutierrez, C. Tags: Poster Session 2 - Treatment: Tissue and Data Banks Source Type: research

Analysis of biomarker expression and biological subtype in primary tumour, corresponding lymph node and distant metastasis with 5-year follow-up
Conclusion: Prognostic information can be obtained by subtype classification using routine-based biomarker analysis in the primary tumour. Preliminary data suggest that the subtype distribution is associated with a worse prognostic profile in the lymph node- and distant metastasis. Detailed survival analysis will be presented at the meeting.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-10-36.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Falck, A.-K., Ferno, M., Bendahl, P.-O., Chebil, G., Olsson, H., Ryden, L. Tags: Poster Session 2 - Prognostic and Predictive Factors: Prognostic Factors - Clinical Source Type: research

Mitotic Component of Grade Can Distinguish Breast Cancer Patients at Greatest Risk of Local Relapse
Conclusion: Within this cohort of tamoxifen treated T1 and T2 breast cancer patients 50 years of age or older, mitotic index could stratify women into groups with high and low risk of recurrence. If validated this may be a useful way of allocating patients to different treatment groups. Additional validation studies are planned on similar groups of patients.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-10-33.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Done, S., Miller, N., Wei, S. W., Pintilie, M., McCready, D., Liu, F.-F., Fyles, A. Tags: Poster Session 2 - Prognostic and Predictive Factors: Prognostic Factors - Clinical Source Type: research

The incidence of false negative of HER2/Neu status in primary breast cancer in the era of standardized testing: a Canadian prospective study.
Conclusion: Our observation confirms that IHC is an adequate test to predict negative HER2 status in primary breast cancer in surgical excision specimens, even when different antibodies and IHC platforms are used. The study supports and justifies the Canadian algorithm of IHC followed by ISH in equivocal cases in view of the extremely low percentage of false negative cases observed. This reflects the strict adherence to internal protocols and mandatory participation in quality assurance programs. These results provide further confirmation that the vast majority of patients eligible for trastuzumab are not deprived from an ...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Hanna, W., Barnes, P., Chang, M., Gilks, B., Magliocco, A., Rees, H., Robertson, S., SenGupta, S., Nofech-Mozes, S. Tags: Poster Session 2 - Prognostic and Predictive Factors: Prognostic Factors - Clinical Source Type: research

Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial
Conclusions: Our results represent the first prospective correlation of different luminal A/B definitions vs. a guideline mentioned gene signature (RS). High RS usually implies high grade and luminal B classification, the converse is not true. There is substantial heterogeneity in risk assessment by luminal A/B classification and grade in low/intermediate RS groups. Concordance for central/local assessment of grade and luminal A/B status was limited. There is strong need for standardization of molecular subtype's immunhistochemical/clinical definition prior to implementation into daily routine. Clinical significance of the...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Gluz, O., Kreipe, H., Kates, R., Christgen, M., Liedtke, C., Shak, S., Clemens, M., Salem, M., Liedtke, B., Aktas, B., Markmann, S., Uleer, C., Augustin, D., Thomssen, C., Nitz, U., Harbeck, N. Tags: Poster Session 2 - Prognostic and Predictive Factors: Prognostic Factors - Clinical Source Type: research

The Mammostrat Test is an Effective Tool to Stratify Patient Samples Previously Characterized as Intermediate by the Oncotype Dx Test
Mammostrat is a well validated, 5-antibody immunohistochemistry (IHC) based assay initially developed to assess the risk of recurrence in patients with early stage estrogen receptor (ER) positive breast cancer. Recent data from the TEAM trial demonstrated that Mammostrat predicted distant relapse free survival (DRFS) for both exemestane and tamoxifen-exemestane treated patients irrespective of nodal status and chemotherapy. OncoType Dx® is a recurrence assay frequently used by oncologists to aid in the selection of early stage breast cancer patients who may benefit from adjuvant chemotherapy. It is currently unclear wh...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Bloom, K., Kyshtoobayeva, A., Hilaire, L., Gutekunst, K. Tags: Poster Session 2 - Prognostic and Predictive Factors: Prognostic Factors - Clinical Source Type: research

Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study
Discussion: This large clinical trial serves both as a clinical validation study of the PAM 50 test and as a demonstration that a complex multi-analyte gene-expression test can be performed in a routine hospital pathology laboratory while meeting the same quality metrics as a central referral laboratory. The results of the primary analysis, when combined with the results already reported from the Trans ATAC population, yield Level 1 evidence for clinical validity of the PAM50 test for predicting the risk of DR in postmenopausal women with ER+ EBC and form the basis of the design of the clinical utility studies of the PAM 5...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Gnant, M., Filipits, M., Mlineritsch, B., Dubsky, P., Jakesz, R., Kwasny, W., Fitzal, F., Rudas, M., Knauer, M., Singer, C., Greil, R., Ferree, S., Storhoff, J., Cowens, J., Schaper, C., Liu, S., Nielsen, T., the ABCSG Tags: Poster Session 2 - Prognostic and Predictive Factors: Prognostic Factors - Clinical Source Type: research

Circulating HER2 extracellular domain (ECD) predicts a poor prognosis for metastatic breast cancer patients
Conclusions: Monitoring the circulating levels of the HER2 ECD in patients with metastatic breast cancer provides a real-time assessment of tumor burden and indicates poor prognosis, and may provide important information for reassessment of HER2 in HER2-negative metastatic breast cancer.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-05-05.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Wang, X.-j., Shao, X.-Y., Xu, X.-H., Chen, Z.-H., Wang, S., Cai, J.-F., Huang, J., Huang, P., Lou, C.-J., Ling, Z.-Q., Han, M. Tags: Poster Session 2 - Tumor Cell and Molecular Biology: Biomarkers Source Type: research

High antitumoral activity of neoadjuvant chemotherapy (NCT) with weekly paclitaxel + capecitabine and trastuzumab in patients with locally advanced HER2+ breast cancer (HER2+ LABC): Preliminary results.
Conclusion:. This NCT provided high pCR, specially in the HR- subgroup with a very favourable toxicity profile and merits further exploration.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-21.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Augereau, P., Raro, P., Verriele, V., Delva, R., Abadie-Lacourtoisie, S., Ceban, T., Paillocher, N., Valo, I., Maillart, P., Soulie, P. Tags: Poster Session 1 - Treatment: Neoadjuvant Chemotherapy Source Type: research

Assessing Prognosis and Therapy Response in Primary Systemic Therapy of Breast Cancer with Magnetic Resonance Spectroscopy
CONCLUSION: Compared to our previous study, we did not confirm that changes in [tCho] were associated with RECIST responses. However, increased MRS-measured [tCho] after 1 day of treatment was associated with reduced OS and IDFS independent of pCR. We conclude that increases in [tCho] might be a negative predictor of chemotherapy benefit.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-11.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Bolan, P., Wey, A., Eberly, L., Nelson, M., Haddad, T., Yee, D., Garwood, M. Tags: Poster Session 1 - Treatment: Neoadjuvant Chemotherapy Source Type: research

Down-regulation of trefoil protein 1(TFF1) in normal breast tissue of postmenopausal women at increased risk for breast cancer on exemestane
Discussion: Assessing tissue biomarkers with repeat core needle biopsies in a phase II prevention trial in high risk women is feasible. Since prevention agents are not universally protective, determining biomarkers of effect may allow tailored therapy. TFF1 is a biologically plausible biomarker of AI activity that was down-regulated in 77% of breast tissue following exemestane therapy. This is the first study to evaluate this tissue marker in the prevention setting. Further study is needed to correlate with other biomarkers of interest, e.g. change in mammographic density, serum hormone levels and clinical outcomes.Citatio...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Gatti-Mays, M., Kallakury, B., Makariou, E., Venzon, D., Permaul, E., Isaacs, C., Cohen, P., Warren, R., Gallagher, A., Eng-Wong, J. Tags: Poster Session 1 - Epidemiology, Risk, and Prevention: Prevention - Clinical Trials Source Type: research

V Array: A novel tool for constructing virtual tissue microarrays (TMAs), an evaluation of its use in optimizing TMA construction for Ductal Carcinoma in Situ (DCIS).
This study aims to determine the number of cores required to construct representative TMAs for different biomarkers in the setting of DCIS.Materials and Methods: Tumor blocks from 102 patients presenting with DCIS alone were retrieved from the archives of Sunnybrook Hospital. Sequential tissue sections were stained with H&E, ER, PgR, HER2 and Ki67. All slides were manually evaluated and Histo-scores determined for ER, and PR, % positive cells for Ki67. and HER2 was classified in accordance with the 2007 ASCO/CAP guidelines. Slides were then scanned at x1.25 magnification on the Ariol SL50 Image Analysis system (Leica M...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Quintayo, M., Starczynski, J., Yan, F., Bartlett, J., Benko, L., Hanna, W., Nofech-Mozes, S., Rakovitch, E. Tags: Poster Session 1 - Prognostic and Predictive Factors: Biomarkers - Methods Source Type: research

Revisiting chromosome 17q copy number aberrations in early high-risk breast cancer
Conclusions: Profiles of 17p11-q11, 17q12 and 17q21-22 copies according to broadly used FISH probes reveal distinct subgroups of breast cancer with possibly different versions of chromosomal instability that are only partially concordant with classical CEN17, HER2 and TOP2A gain status. The prognostic significance of these profiles seems to depend on tumor proliferation and hormonal status, as well as on the extent of the affected areas on 17q. Validation of these profiles for prospective application may aid in a more accurate assessment of early high-risk breast cancer patients.Citation Information: Cancer Res 2012;72(24 ...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Kotoula, V., Bobos, M., Eleftheraki, A., Timotheadou, E., Razis, E., Goussia, A., Levva, S., Kalogeras, K., Pectasides, D., Fountzilas, G. Tags: Poster Session 1 - Prognostic and Predictive Factors: Biomarkers - Methods Source Type: research

Using Natural Language Processing to Identify and Extract HER2 Value from a large EMR system
This study used Natural Language Processing (NLP) technology to identify and extract HER2 status. NLP results were validated by comparison with cancer registry data and any discrepancies were manually reviewed.Method: We assembled a cohort of 2,846 breast cancer patients from the membership of a health plan based in southern California, Kaiser Permanente. All free text notes including pathology reports, progress notes, and discharge summaries were extracted from our electronic medical record (EMR) system. A window of 9 months before and after the diagnosis date was applied to restrict the number of notes needed to be proce...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Zheng, C., Avila, C., Haque, R. Tags: Poster Session 1 - Prognostic and Predictive Factors: Biomarkers - Methods Source Type: research

Estrogen receptor positivity: 10% or 1%?
Conclusion. Patients whose tumors are ER-positive at 1–10% have clinical and pathologic characteristics different from those whose tumors are ER-positive ≥10%. Similar to patients whose tumors are ER negative, those with ER-positive disease at 1–10% do not appear to benefit from endocrine therapy.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-07-09.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Yi, M., Huo, L., Koenig, K., Mittendorf, E., Meric-Bernstam, F., Kuerer, H., Bedrosian, I., Symmans, W., Hortobagyi, G., Crow, J., Shah, R., Hunt, K. Tags: Poster Session 1 - Prognostic and Predictive Factors: Biomarkers - Methods Source Type: research

Attainment of extremely high concordance rates between fluorescence in situ hybridization and immunohistochemistry in testing for human epidermal growth factor receptor 2 (HER2) in breast cancer using a normalized scoring system for immunohistochemistry: a four year experience with over 9000 cases
Discussion: Extremely high concordance rates, with elimination of the vast majority of false IHC positive cases, can be attained in a clinical laboratory examining tissues from divergent sources, even in the absence of controlling pre-analytical variables, by employing a normalized scoring system for IHC.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-07-01.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Gown, A., Goldstein, L., Tse, C., Hwang, H., Kandalaft, P. Tags: Poster Session 1 - Prognostic and Predictive Factors: Biomarkers - Methods Source Type: research

Microvessel density as determined by computerized image analysis of CD34 and CD105 expression correlates with poor outcome in triple-negative breast cancer
Conclusions: Our findings demonstrate significant associations between MVD in different tumoral areas and various parameters in triple-negative breast tumors, indicating that TNCs with aggressive features have higher MVDs. Furthermore, peripheral tumoral CD105 MVD is a strong, independent prognostic factor in TNC. Finally, blood vessels are mainly located in the peripheral area of TNCs and seem to have a critical role in tumor progression by representing means for disease dissemination.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-06-03.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: De Brot, M., Rocha, R., Soares, F., Gobbi, H. Tags: Poster Session 1 - Tumor Cell and Molecular Biology: Angiogenesis Source Type: research

milk deposition in women's mammary duct has been a potential risk factor of breast tumor
Discussion: Diagnosis of duct milk deposition, which may not necessarily presented by nipple discharge, is the most common finding and associated with proliferation and thus intraductal mass, etc. we should noticed 30–50 years old women groups, cause they have have stopped breast-feeding for years but still had yellow or brown, liquid or solid milk-like things in their lactiferous ducts. We predict duct milk deposition may be related with breast carcinogenesis. It is a kind of long time mechanical stimulation in the duct, both the physico-chemical properties and the acid-alkaline environment had changes by years. Sti...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Xu, Z., Gu, Y., Gong, G., Zhang, Y. Tags: Poster Session 1 - Tumor Cell and Molecular Biology: Etiology/Carcinogenesis Source Type: research

Novel diagnostic procedure of metastasis to the sentinel lymph node of breast cancer using a semi-dry dot-blot method
Conclusions: The SDB method is simple, fast, accurate and cost-effective for the intra-operative diagnosis of SLN metastasis. Because there is no loss of lymph node tissue, the SDB method and pathological investigation can be performed simultaneously.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-27.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Otsubo, R., Oikawa, M., Shibata, K., Hirakawa, H., Yano, H., Matsumoto, M., Hatachi, T., Nakao, K., Hayashi, T., Abe, K., Kinoshita, N., Nakashima, M., Taniguchi, H., Omagari, T., Itoyanagi, N., Nagayasu, T. Tags: Poster Session 1 - Detection/Diagnosis: Axillary Staging and Sentinel Nodes Source Type: research

The utility of axillary ultrasound and sentinel lymph node biopsy in the management of metaplastic breast carcinoma
Conclusions: For clinically node-negative MBC patients, our contemporary data series suggests the incidence of occult LN metastasis is sufficiently high to warrant LN staging especially for patients with intermediate and high-grade tumors. This can be accomplished in a minimally invasive fashion with reasonable accuracy (~97%) with axillary US, FNAB of sonographically suspicious LNs, and SLNB for patients with negative axillary US or FNAB. Axillary LND should be performed for patients with clinically and/or FNAB-positive LN for enhanced disease control.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-22.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Hieken, T., Fazzio, R., Reynolds, C., Jones, K., Ghosh, K., Glazebrook, K. Tags: Poster Session 1 - Detection/Diagnosis: Axillary Staging and Sentinel Nodes Source Type: research

Sentinel Lymph Node detection after previous breast tumour surgical resection: identification rate and false negative rate through a prospective multi institutional study.
Conclusions: After previous surgical resection of early breast cancer, ASLND remains feasible with a low identification rate of 86%, despite the use of the combined method. The False negative rate is acceptable with the use of IHC.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-21.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Classe, J.-M., Andrieux, N., de Lara Tunon, C., Charitansky, H., Lecuru, F., Houpeau, J.-L., Faure, C., De Blaye, P., Houvenaeghel, G., Kere, D., Marchal, F., Raro, P., Lefebvre, C., Dupre, P.-F., Rodier, J.-F. Tags: Poster Session 1 - Detection/Diagnosis: Axillary Staging and Sentinel Nodes Source Type: research

Intraoperatively-palpable "non-sentinel" nodes: should they be removed?
Conclusion: pNSNs provide information that changes the surgical plan by ACOSOG Z0011 criteria in 14% of cases. Whether their removal changes patient outcomes remains unclear, especially as SNs and pNSNs may, together, be falsely-negative for ECE present within the axilla. While we recommend their removal at this time based upon the added information they provide, further study is required to determine whether the changes resulting from pNSN dissection (i.e. need for ALND) provide any outcome benefit in this era of effective systemic therapy.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-16.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Crivello, M., Ruth, K., Sigurdson, E., Egleston, B., Boraas, M., Bleicher, R. Tags: Poster Session 1 - Detection/Diagnosis: Axillary Staging and Sentinel Nodes Source Type: research

The Performance of the One Step Nucleic acid Amplification (OSNA) Assay in Breast Cancer Patients with Receiving Preoperative Systemic Therapy
Conclusion & Discussion: These results indicate the OSNA assay can be applicable for breast cancer patients after receiving PST as well as breast cancer patients without receiving PST. The OSNA assay will enable to examine the whole portion of nodes, leading to more detection of metastases (especially micrometastases) and more exact nodal staging for breast cancer patients treated by PST. Also, for the patients who receive sentinel lymph node biopsy after PST, the OSNA assay will be useful as intraoperative examination method of SLNs because it is expected to provide more correct judgments than current intraoperative m...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Yagata, H., Yamauchi, H., Horii, R., Osako, T., Iwase, T., Akiyama, F., Kinoshita, T., Tsuda, H., Tsugawa, K., Nakamura, S. Tags: Poster Session 1 - Detection/Diagnosis: Axillary Staging and Sentinel Nodes Source Type: research

The Institut Curie Nomogram including HER2 status predicts additional axillary metastasis in breast cancer patients with a positive sentinel node biopsy: a multicentric validation.
Conclusions: We demonstrated the robustness and accuracy of the first nomogram that includes HER2 status in the prediction of additional axillary metastasis. Moreover, a calculated risk under 10% was defined as a cut-off to avoid axillary lymph node dissection, leading to low rates of neglected residual axillary disease.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-07.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Ngo, C., De Rycke, Y., Belichard, C., Guilhen, N., Doridot, V., Rouzier, R., Coutant, C., Hudry, D., Fritel, X., Fourchotte, V., Feron, J.-G., Pierga, J.-Y., Salomon, A., Alran, S. Tags: Poster Session 1 - Detection/Diagnosis: Axillary Staging and Sentinel Nodes Source Type: research

Fluorescence mapping with indocyanine green for sentinel lymph node detection in early breast cancer - results of the ICG-10 study
Conclusion: ICG fluorescence imaging permits real-time visualization of lymphatics and provides an additional dimension to SLN biopsy which is safe and effective. These results confirm high sensitivity for fluorescence in SLN identification and the combined nodal sensitivity for ICG and blue dye (95.0%) was higher than for blue dye and radioisotope (73.1%). With further refinements in the technique may it may be possible to eventually rely on ICG as a sole tracer agent. Moreover, a marginally higher nodal yield with fluorescent mapping may allow more confident omission of completion axillary dissection in selected SLN posi...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Benson, J., Loh, S.-W., Jones, L., Wishart, G. Tags: Poster Session 1 - Detection/Diagnosis: Axillary Staging and Sentinel Nodes Source Type: research

PROMIS: Prospective Registry Of MammaPrint in breast cancer patients with an Intermediate recurrence Score
The objectives of the study are to: 1. Describe the frequency of chemotherapy + endocrine versus endocrine-alone decisions in Oncotype DX intermediate score patients.2. Assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine-alone treatment decisions.3. Assess the distribution of MammaPrint Low and High Risk in patients with an intermediate recurrence score.4. Assess concordance of TargetPrint ER, PR and HER2 results with Oncotype DX ER, PR and HER2 and with locally assessed IHC/FISH ER, PR and HER2.5. Compare clinical subtype based on IHC/FISH ER, PR, HER2 and Ki-67 (if available) with BluePrint molec...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Soliman, H., Untch, S., Stork-Sloots, L. Tags: Ongoing Trials 3 - Response Prediction Source Type: research

SHARE. A French multiceter phase III trial comparing accelerated partial irradiation (APBI) versus standard or hypofractionated whole breast irradiation in low risk of local recurrence breast cancer
Conclusion: In summary, the French trial will allow: – Selected patients according to age and low risk of local recurrence parameters.– To evaluate in a subgroup of patients (4 to 5 centers), the impact of magnetic resonance imaging (MRI) for patient selection and the rate of occult disease (multifocality) not detected by standard imaging evaluation which is considered as an exclusion criteria.– To determine APBI parameters adapted to the surgical procedure in the tumor bed remodeling setting.– To determine homogeneous criteria for the surgical procedure, minimal requirements and optimal criteria th...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Belkacemi, Y., Bourgier, C., Kramar, A., Lemonier, J., Auzac, G., Dumas, I., Lacornerie, T., Mijonnet, S., Mege, J.-P., Lartigau, E. Tags: Ongoing Trials 1 - Radiation Therapy Source Type: research

Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)
Conclusion: The HRD score is significantly correlated with pathologic response to platinum-based chemotherapy in early-stage triple-negative and BRCA1/2 mutation-associated BC.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD09-04.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Telli, M., Jensen, K., Abkevich, V., Hartman, A.-R., Vinayak, S., Lanchbury, J., Gutin, A., Timms, K., Ford, J. Tags: Poster Discussion 9 - DNA Repair Source Type: research

St. Gallen 2011 clinicopathological subtyping of breast cancer: impact of different proliferation assessment methods
Conclusions: The delimination of Luminal A and Luminal B Her2 negative BCs according to the St. Gallen Consensus 2011 is highly influenced by the method of proliferation assessment. Using the recommended cut-off <14% all estimations of Ki67LI came out with Luminal A/Luminal B ratios (10–34% vs. 45–69%) which are much lower than those published (44–53% vs. 9–29%). As a consequence, this could lead to more cytotoxic treatment. Therefore, the biological relevance of KI67LI seems to be not unequivocal. Unlike this, proliferation measurement by MAI resulting in a Luminal A/Luminal B ratio of 52% vs. 2...
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Focke, C., Glaser, D., Finsterbusch, K., Decker, T. Tags: Poster Discussion 6 - Ki67 Source Type: research

Development of a highly reproducible clinical test for Ki67 using AQUA technology
Discussion: The use of image analysis has been shown to be of significant value in expression assessment due to increased objectivity and the potential for broader standardization. We have demonstrated that the use of advanced image analysis when coupled with fluorescence immunohistochemistry can produce a system with greatly improved precision over traditional IHC methods in clinically relevant samples. These results indicate that image analysis of Ki67 is advantageous over manual IHC in clinical diagnostic assessment.Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD06-03.
Source: Cancer Research - December 17, 2012 Category: Cancer & Oncology Authors: Murphy, D., Pacia, E., Beruti, S., Lamoureux, J., Dabbas, B., Diver, J., Christiansen, J. Tags: Poster Discussion 6 - Ki67 Source Type: research